7D3I

Crystal structure of SARS-CoV-2 main protease in complex with MI-23

7D3I の概要

• エントリーDOI: 10.2210/pdb7d3i/pdb
• 分子名称: 3C-like proteinase, (3~{S},3~{a}~{S},6~{a}~{R})-2-[3-[3,5-bis(fluoranyl)phenyl]propanoyl]-~{N}-[(2~{S})-1-oxidanylidene-3-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]-3,3~{a},4,5,6,6~{a}-hexahydro-1~{H}-cyclopenta[c]pyrrole-3-carboxamide, 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, ... (4 entities in total)
• 機能のキーワード: coronavirus, protease, inhibitor, complex, viral protein., viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 34409.19

構造登録者

Zeng, R.,Li, Y.S.,Qiao, J.X.,Wang, Y.F.,Yang, S.Y.,Lei, J. (登録日: 2020-09-19, 公開日: 2020-10-07, 最終更新日: 2023-11-29)

主引用文献

Qiao, J.,Li, Y.S.,Zeng, R.,Liu, F.L.,Luo, R.H.,Huang, C.,Wang, Y.F.,Zhang, J.,Quan, B.,Shen, C.,Mao, X.,Liu, X.,Sun, W.,Yang, W.,Ni, X.,Wang, K.,Xu, L.,Duan, Z.L.,Zou, Q.C.,Zhang, H.L.,Qu, W.,Long, Y.H.,Li, M.H.,Yang, R.C.,Liu, X.,You, J.,Zhou, Y.,Yao, R.,Li, W.P.,Liu, J.M.,Chen, P.,Liu, Y.,Lin, G.F.,Yang, X.,Zou, J.,Li, L.,Hu, Y.,Lu, G.W.,Li, W.M.,Wei, Y.Q.,Zheng, Y.T.,Lei, J.,Yang, S.
SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model.
Science, 371:1374-1378, 2021

PubMed Abstract: The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M in complex with MI-23, one of the most potent compounds, revealed its interaction mode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment with MI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats.

PubMed: 33602867
DOI: 10.1126/science.abf1611

実験手法

X-RAY DIFFRACTION (2.004 Å)